312300-42-8

Basic information

• Product Name: 6-METHOXY-PYRIDINE-3-SULFONYL CHLORIDE
• Synonyms: 6-METHOXY-PYRIDINE-3-SULFONYL CHLORIDE;6-Methoxypyridine-3-sulphonyl chloride;3-(Chlorosulphonyl)-6-methoxypyridine;5-(Chlorosulphonyl)-2-methoxypyridine;6-(Methyloxy)-3-pyridinesulfonyl chloride
• CAS NO: 312300-42-8
• Molecular Formula: C₆H₆ClNO₃S
• Molecular Weight: 207.63
• Mol File: 312300-42-8.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 320.433 °C at 760 mmHg
• Flash Point: 147.593 °C
• Appearance: White/Crystalline Low Melting Solid
• Density: 1.449 g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.534
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: -3.56±0.11(Predicted)
• CAS DataBase Reference: 6-METHOXY-PYRIDINE-3-SULFONYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-METHOXY-PYRIDINE-3-SULFONYL CHLORIDE(312300-42-8)
• EPA Substance Registry System: 6-METHOXY-PYRIDINE-3-SULFONYL CHLORIDE(312300-42-8)

Safety Data

• Hazard Codes: Xi
• Statements: 36-43
• Safety Statements: 26-36/37
• Hazardous Substances Data: 312300-42-8(Hazardous Substances Data)

Usage

Description

6-METHOXY-PYRIDINE-3-SULFONYL CHLORIDE is an organic compound that serves as a key intermediate in the synthesis of various pharmaceuticals and bioactive molecules. It is characterized by its reactivity and functional groups, which allow it to participate in a range of chemical reactions, making it a versatile building block in the development of new drugs and therapeutic agents.

Uses

Used in Pharmaceutical Synthesis:
6-METHOXY-PYRIDINE-3-SULFONYL CHLORIDE is used as a reactant for the preparation of sulfonate analogs of combretastatin A-4, which are potent antimitotic agents. These analogs have the potential to disrupt microtubule dynamics, leading to the inhibition of cell division and the eventual death of cancerous cells.
Used in Anticancer Applications:
In the pharmaceutical industry, 6-METHOXY-PYRIDINE-3-SULFONYL CHLORIDE is used as a building block for the development of compounds with H+,K+-ATPase inhibitory action. These compounds can help in the treatment of gastric acid-related disorders by reducing the secretion of gastric acid, thus providing relief from symptoms and promoting healing.
Used in Gastric Acid Secretion Inhibition:
6-METHOXY-PYRIDINE-3-SULFONYL CHLORIDE is also used in the synthesis of compounds with gastric acid secretion inhibitory activities. These compounds can be employed in the development of medications for the treatment of conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and other acid-related disorders, by reducing the amount of acid produced in the stomach and alleviating symptoms.

InChI:InChI=1/C6H6ClNO3S/c1-11-6-3-2-5(4-8-6)12(7,9)10/h2-4H,1H3

Upstream product

• 6628-77-9 6-methoxy-pyridin-3-ylamine 
• 13472-85-0 2-methoxy-5-bromopyridine 
• 10167-97-2 2-amino-5-methoxypyridine 

Downstream Products

• 312299-87-9 3,4,5-trimethoxyphenyl 6-methoxy-3-pyridinesulfonate 
• 881676-92-2 1-[(6-methoxypyridin-3-yl)sulfonyl]-5-phenyl-1H-pyrrole-3-carbaldehyde 
• 1138034-16-8 sodium 6-methoxypyridine-3-sulfinate 
• 856955-32-3 6-methoxypyridine-3-sulfonamide 

Relevant articles and documents

DOCK1-INHIBITING COMPOUND AND USE THEREOF

Provided is a compound that is usable as an active ingredient of an anticancer agent. Preferably provided is a compound that has DOCK1-inhibiting activity and exerts an anticancer effect based on the activity. A compound represented by the following formula (A) or a salt thereof: wherein X represents a carbon atom or a nitrogen atom; Y represents an oxygen atom, a hydroxy group, or a hydrocarbon group; R1 and R2 are different, and each represents a hydrogen atom or a group represented by the following formula (A-1): (wherein R6 represents a pyrrolidino group or a phenyl group, and n2 is 0 or 1) ; R3 represents -CO-R7 (wherein R7 is an alkoxy group, an alkyl group, or an alkylamino group), a 1,3-oxazole group, an alkylhydroxy group, a hydrogen atom, or an oxygen atom; R4 represents a hydrogen atom, an oxygen atom, or a hydrocarbon group in which one or more hydrogen atoms may be replaced by one or more substituents; R5 represents a halogen atom, a halogenated alkyl group, or a halogenated alkylthio group; and n1 is an integer of 0 to 5; and

Proton pump inhibitors

A proton pump inhibitor containing a compound represented by the formula (I) wherein X and Y are the same or different and each is a bond or a spacer having 1 to 20 carbon atoms in the main chain, R 1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R 2 , R 3 and R 4 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted thienyl group, an optionally substituted benzo[b]thienyl group, an optionally substituted furyl group, an optionally substituted pyridyl group, an optionally substituted pyrazolyl group, an optionally substituted pyrimidinyl group, an acyl group, a halogen atom, a cyano group or a nitro group, R 5 and R 6 are the same or different and each is a hydrogen atom or an optionally substituted hydrocarbon group, which has a superior proton pump action and shows an antiulcer activity and the like after conversion to a proton pump inhibitor in the body, or a salt thereof. or a prodrug thereof is provided.

COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS

Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of the p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the p38 MAPK by the compound. Also disclosed are derivatives and analogs of pirfenidone, useful for modulating a stress activated protein kinase (SAPK) system.